Unknown Author
January 23, 2026
Sidley Represents Gamma Biosciences on the Divestiture of Univercells Technologies

1 min
AI-made summary
- Sidley advised Gamma Biosciences, a life sciences platform established by KKR, in the sale of its operating company, Univercells Technologies, to Donaldson Company, Inc
- Univercells Technologies specializes in biomanufacturing technologies for advanced therapies and vaccine production
- The Sidley team involved lawyers from multiple practice areas, including M&A, private equity, global finance, antitrust, tax, real estate, labor, privacy, and litigation, led by David Zampa and Adam Runcorn.
Sidley represented Gamma Biosciences, a life sciences platform created by global investment firm KKR to address the advanced therapy bioprocessing market, in the divestiture of its operating company, Univercells Technologies, a leading provider of novel biomanufacturing technologies for flexible and scalable advanced therapies and vaccine production, to Donaldson Company, Inc (NYSE: DCI).
The Sidley team was led by David Zampa and Adam Runcorn (M&A and Private Equity), and included Zoe Woodhouse, Andrew N. Cebula, Jessica Edwards, Stanley Amoah, and Masie Awala (M&A and Private Equity); William Gwyn and Esther Crang (Global Finance); Sven De Knop, Jen Fernandez, and Alessandra Moroni (Global Arbitration, Trade and Advocacy); Patrick J. Harrison, Edward W. Sharon, and Bethany Wise (Antitrust/Competition); Maria Isabel Manley and Zina Chatzidimitriadou (Food, Drug and Medical Device); Jason Menzies, Suresh T. Advani, Wondha Cadet, and Fraser Tudor (Tax); Jade Williams-Adedeji and Michael Condlyffe (Real Estate); Peter McCorkell and Maeve Gillespie (Labor, Employment and Immigration); Francesca Blythe and Eleanor Dodding (Privacy and Cybersecurity); and Samantha Cumming (Commercial Litigation and Disputes).~~Sidley represented Gamma Biosciences, a life sciences platform created by global investment firm KKR to address the advanced therapy bioprocessing market, in the divestiture of its operating company, Univercells Technologies, a leading provider of novel biomanufacturing technologies for flexible and scalable advanced therapies and vaccine production, to Donaldson Company, Inc (NYSE: DCI).
The Sidley team was led by David Zampa and Adam Runcorn (M&A and Private Equity), and included Zoe Woodhouse, Andrew N. Cebula, Jessica Edwards, Stanley Amoah, and Masie Awala (M&A and Private Equity); William Gwyn and Esther Crang (Global Finance); Sven De Knop, Jen Fernandez, and Alessandra Moroni (Global Arbitration, Trade and Advocacy); Patrick J. Harrison, Edward W. Sharon, and Bethany Wise (Antitrust/Competition); Maria Isabel Manley and Zina Chatzidimitriadou (Food, Drug and Medical Device); Jason Menzies, Suresh T. Advani, Wondha Cadet, and Fraser Tudor (Tax); Jade Williams-Adedeji and Michael Condlyffe (Real Estate); Peter McCorkell and Maeve Gillespie (Labor, Employment and Immigration); Francesca Blythe and Eleanor Dodding (Privacy and Cybersecurity); and Samantha Cumming (Commercial Litigation and Disputes).
Article Author
Unknown Author
The Sponsor
